Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study
Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Claudia Trojaniello(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Antonio Sorrentino(Roche (Switzerland)), Daniela Massi(University of Florence), Miriam Paone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Eleonora Cioli(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Massimo Guidoboni(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Gerardo Ferrara(Azienda Ospedaliera G.Rummo), Mariaelena Capone(Istituto di Chimica Biomolecolare), Francesco Spagnolo(Martin University), Pietro Quaglino(Department of Medical Sciences), Paola Queirolo, Luisa Fioretto(Ospedale SS. Annunziata), Diana Giannarelli(Agostino Gemelli University Polyclinic), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Ketty Peris(Agostino Gemelli University Polyclinic), Corrado Caracò(Istituto di Chimica Biomolecolare)
Cited by 3
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k